Xinnate
Pre-clinicalInspired by the body’s own defense mechanisms, TCP-25 was developed from thrombin-derived peptides discovered by Professor Arthur Schmidtchen, MD, and team at Lund University. By rebalancing the immune response, TCP-25 offers a powerful therapeutic approach for complex skin disorders.
Founded
2019
Focus
RNA & Gene Therapy
About
Inspired by the body’s own defense mechanisms, TCP-25 was developed from thrombin-derived peptides discovered by Professor Arthur Schmidtchen, MD, and team at Lund University. By rebalancing the immune response, TCP-25 offers a powerful therapeutic approach for complex skin disorders.
Company Info
TypePrivate
Founded2019
LocationGothenburg, Sweden
StagePre-clinical
Contact
SIMILAR COMPANIES
Basic Genomics
Pre-clinical · Stockholm
2A Pharma
Phase 1 · Stockholm
Abliva
Pre-clinical · Lund
Affibody
Phase 1 · Solna
Alligator Bioscience
Phase 1 · Lund
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile